Retatrutide vs Tirzepatide

Retatrutide and tirzepatide are both synthetic incretin peptides from Eli Lilly, and they are constantly discussed as though one is simply a stronger version of the other. Mechanistically they are not. Tirzepatide activates two receptors. Retatrutide activates three — and the third one operates on an entirely different physiological lever.

Retatrutide vs Tirzepatide at a Glance

	Retatrutide	Tirzepatide
Class	Triple agonist	Dual agonist
Receptors	GIP · GLP-1 · Glucagon	GIP · GLP-1
Length	39 amino acids	39 amino acids
Developer	Eli Lilly	Eli Lilly
Stage	Phase 3 (TRIUMPH)	Approved
Approved in Canada?	No — not approved anywhere	Yes — Mounjaro, Zepbound
Peak trial weight reduction	24.2% at 48 weeks (Phase 2) 28.7% at 68 weeks (Phase 3)	20.9% at 72 weeks (SURMOUNT-1)
Trial doses	1 / 4 / 8 / 12 mg weekly	5 / 10 / 15 mg weekly
Half-life	~6 days	~5 days
Liver fat reduction	−82.4% (12 mg)	Not the primary signal
Head-to-head trial?	None published

The Mechanism: What the Third Receptor Changes

Tirzepatide binds two receptors: GIP and GLP-1. Both are incretin receptors — they sit in the pathway that responds to food. Agonism at both produces glucose-dependent insulin secretion, delayed gastric emptying, and central appetite suppression.

Retatrutide binds those same two, and adds glucagon.

That third receptor is the entire story, and it is not a matter of degree. GLP-1 and GIP agonism reduce intake. Glucagon agonism is associated in the literature with increased energy expenditure — output rather than input. Retatrutide operates on both sides of the energy balance equation. Tirzepatide operates on one.

It is also the riskier design. Glucagon agonism was historically avoided in metabolic drug development for an obvious reason: glucagon raises blood glucose, which is the opposite of what a diabetes drug should do. The bet retatrutide is testing is that the incretin arms offset the glycemic cost while the energy-expenditure benefit is retained.

The evidence the glucagon arm is doing real work

It is not the weight data. It is the liver.

A Phase 2a substudy examined participants with metabolic dysfunction-associated steatotic liver disease. At the 12 mg dose, mean liver fat fell by 82.4% at 24 weeks. 86% of participants reached normal liver fat. In the placebo group: zero.

Glucagon receptor agonism drives hepatic fatty acid oxidation. That is the mechanism doing precisely what the pharmacology predicts, in the organ where it should be visible. It is the clearest available evidence that the third receptor is not decorative — and it is why retatrutide’s Phase 3 programme extends beyond weight management.

Trial Results Compared

Tirzepatide — a completed programme

SURMOUNT-1 (Jastreboff et al., NEJM, 2022) randomised 2,539 adults with obesity to weekly tirzepatide at 5, 10, or 15 mg, or placebo, over 72 weeks. Mean weight reduction ran from 16.0% (5 mg) to 20.9% (15 mg), versus 3.1% on placebo. At the highest dose, 39.7% of participants lost at least 25% of body weight.

The SURPASS programme established its glycemic effects in type 2 diabetes. Tirzepatide reached approval on this record.

Retatrutide — a programme still running

The Phase 2 trial (Jastreboff et al., NEJM, June 2023) randomised 338 adults to weekly retatrutide at 1, 4, 8, or 12 mg, or placebo, over 48 weeks. Mean weight reduction: 8.7% (1 mg), 17.1% (4 mg), 22.8% (8 mg), 24.2% (12 mg), versus 2.1% on placebo. At the highest dose, 26% of participants lost at least 30%.

And the curves had not plateaued at 48 weeks. The trial ended before the effect did.

The first Phase 3 readout (TRIUMPH, December 2025) reported up to 28.7% at 68 weeks — higher again, over a longer period.

Three cautions on that comparison — and they matter

1. No head-to-head trial has been published. Retatrutide has never been tested directly against tirzepatide. Every comparison between them, including this one, is cross-trial inference.
2. The trials are not comparable by design. Different durations (48 vs 72 weeks), different populations, different protocols, different endpoints. They were never built to be compared against each other.
3. Retatrutide’s headline figure is Phase 2. Effect sizes commonly move between Phase 2 and Phase 3, and 338 participants is not enough to detect rare adverse events. Tirzepatide’s figure comes from a completed programme; retatrutide’s is an interim signal.

A larger number from a smaller, shorter, unfinished trial is not evidence of superiority. It is a reason to keep watching.

Side Effects Compared

Both show the incretin-class profile. Gastrointestinal effects — nausea, vomiting, diarrhea — are the most frequently reported in both programmes, and are dose-related in both. Both escalated doses gradually for exactly that reason.

Specific to retatrutide: escalation has been associated in the trial record with paresthesia — tingling, numbness, or prickling. This is not a general GLP-1 class effect; it appears in the retatrutide record specifically.

The asymmetry that matters: tirzepatide’s safety profile is established through the approval process. Retatrutide’s is not. Its Phase 3 programme is ongoing, long-term human safety data does not exist, and rare adverse events — if there are any — may not yet have been detected.

Regulatory Status in Canada

This is the difference that matters most, and it is not mechanistic.

Tirzepatide is an approved prescription drug in Canada — Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), both carrying a Drug Identification Number. Anyone seeking tirzepatide as a medication should obtain an authorized product on prescription from a licensed pharmacy.

Retatrutide is not approved in Canada, the United States, or any other jurisdiction. There is no authorized retatrutide product anywhere in the world — not because access is restricted, but because the compound has not completed clinical development.

Neither is a controlled substance. CompoundPlug supplies both strictly as research chemicals for in-vitro and in-vivo laboratory research. See Research Use Only.

In Summary

Retatrutide and tirzepatide differ by a single receptor, and that one receptor changes the mechanism from reduce intake to reduce intake and increase expenditure. The liver-fat data is the clearest evidence that it works as designed.

Retatrutide’s Phase 2 signal is the largest reported in the incretin class. It is also the least established: an ongoing Phase 3 programme, no approval anywhere, no long-term safety data, and no head-to-head trial against the compound it is constantly compared to.

Tirzepatide is the known quantity — approved, DIN-bearing, with a completed trial programme behind it.

Both are supplied by CompoundPlug for laboratory research only.

• Retatrutide (RETA) — 10mg, 20mg, 30mg. HPLC and mass-spec verified.
• Tirzepatide (TIRZ) — 10mg, 20mg, 30mg. HPLC and mass-spec verified.
• Semaglutide vs Tirzepatide — the one comparison in this category with a head-to-head trial behind it.
• GLP-1 Peptides — the full category.

Frequently Asked Questions